1
|
Agarwal U, Verma S, Tonk RK. Chromenone: An emerging scaffold in anti-Alzheimer drug discovery. Bioorg Med Chem Lett 2024; 111:129912. [PMID: 39089526 DOI: 10.1016/j.bmcl.2024.129912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2024] [Revised: 07/11/2024] [Accepted: 07/26/2024] [Indexed: 08/04/2024]
Abstract
Alzheimer's disease (AD) presents a growing global health concern. In recent decades, natural and synthetic chromenone have emerged as promising drug candidates due to their multi-target potential. Natural chromenone, quercetin, scopoletin, esculetin, coumestrol, umbelliferone, bergapten, and methoxsalen (xanthotoxin), and synthetic chromenone hybrids comprising structures like acridine, 4-aminophenyl, 3-arylcoumarins, quinoline, 1,3,4-oxadiazole, 1,2,3-triazole, and tacrine, have been explored for their potential to combat AD. Key reactions used for synthesis of chromenone hybrids include Perkin and Pechmann condensation. The activity of chromenone hybrids has been reported against several drug targets, including AChE, BuChE, BACE-1, and MAO-A/B. This review comprehensively explores natural, semisynthetic, and synthetic chromenone, elucidating their synthetic routes, possible mode of action/drug targets and structure-activity relationships (SAR). The acquired knowledge provides valuable insights for the development of new chromenone hybrids against AD.
Collapse
Affiliation(s)
- Uma Agarwal
- Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi 110017, India
| | - Saroj Verma
- Pharmaceutical Chemistry Division, School of Medical and Allied Sciences, K.R. Mangalam University, Gurugram 122103, India.
| | - Rajiv K Tonk
- Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences & Research University, Delhi 110017, India.
| |
Collapse
|
2
|
Abstract
Propargylamine is a chemical moiety whose properties have made it a widely distributed group within the fields of medicinal chemistry and chemical biology. Its particular reactivity has traditionally popularized the preparation of propargylamine derivatives using a large variety of synthetic strategies, which have facilitated the access to these compounds for the study of their biomedical potential. This review comprehensively covers and analyzes the applications that propargylamine-based derivatives have achieved in the drug discovery field, both from a medicinal chemistry perspective and from a chemical biology-oriented approach. The principal therapeutic fields where propargylamine-based compounds have made an impact are identified, and a discussion of their influence and growing potential is included.
Collapse
|
3
|
In vitro and in silico investigation of inhibitory activities of 3-arylcoumarins and 3-phenylazo-4-hydroxycoumarin on MAO isoenzymes. Struct Chem 2022. [DOI: 10.1007/s11224-022-02092-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
7,8-Dihydroxycoumarin derivatives: In silico molecular docking and in vitro anticholinesterase activity. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.134535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
5
|
Pintus F, Floris S, Fais A, Era B, Kumar A, Gatto G, Uriarte E, Matos MJ. Hydroxy-3-Phenylcoumarins as Multitarget Compounds for Skin Aging Diseases: Synthesis, Molecular Docking and Tyrosinase, Elastase, Collagenase and Hyaluronidase Inhibition, and Sun Protection Factor. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27206914. [PMID: 36296507 PMCID: PMC9611449 DOI: 10.3390/molecules27206914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 10/11/2022] [Accepted: 10/12/2022] [Indexed: 11/21/2022]
Abstract
Skin aging is a progressive biological process of the human body, and it is not only time-dependent. Differently substituted 3-phenylcoumarins proved to efficiently inhibit tyrosinase. In the current work, new substitution patterns have been explored, and the biological studies were extended to other important enzymes involved in the processes of skin aging, as elastase, collagenase and hyaluronidase. From the studied series, five compounds presented inhibitory activity against tyrosinase, one compound against elastase, eight compounds against collagenase and two compounds against hyaluronidase, being five compounds dual inhibitors. The 3-(4'-Bromophenyl)-5,7-dihydroxycoumarin (1) and 3-(3'-bromophenyl)-5,7-dihydroxycoumarin (2) presented the best profiles against tyrosinase (IC50 = 1.05 µM and 7.03 µM) and collagenase (IC50 = 123.4 µM and 110.4 µM); the 3-(4'-bromophenyl)-6,7-dihydroxycoumarin (4) presented a good inhibition against tyrosinase and hyaluronidase; the 3-(3'-bromophenyl)-6,7-dihydroxycoumarin (5) showed an effective tyrosinase and elastase inhibition; and 6,7-dihydroxy-3-(3'-hydroxyphenyl)coumarin (11) presented a dual profile inhibition against collagenase and hyaluronidase. Furthermore, considering the overall activities tested, compounds 1 and 2 proved to be the most promising anti-aging compounds. These compounds also showed to have a photo-protective effect, without being cytotoxic to human skin keratinocyte cells. To predict the binding site with the target enzymes, computational studies were also carried out.
Collapse
Affiliation(s)
- Francesca Pintus
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy
| | - Sonia Floris
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy
| | - Antonella Fais
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy
- Correspondence: (A.F.); (M.J.M.)
| | - Benedetta Era
- Department of Life and Environmental Sciences, University of Cagliari, 09042 Monserrato, Italy
| | - Amit Kumar
- Department of Electrical and Electronic Engineering, University of Cagliari, 09123 Cagliari, Italy
| | - Gianluca Gatto
- Department of Electrical and Electronic Engineering, University of Cagliari, 09123 Cagliari, Italy
| | - Eugenio Uriarte
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade Santiago de Compostela, 15782 Santiago de Compostela, Spain
- Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile, Santiago 7500912, Chile
| | - Maria João Matos
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade Santiago de Compostela, 15782 Santiago de Compostela, Spain
- Correspondence: (A.F.); (M.J.M.)
| |
Collapse
|
6
|
Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versus trans-6-Styrylcoumarin. Molecules 2022; 27:molecules27030928. [PMID: 35164192 PMCID: PMC8838197 DOI: 10.3390/molecules27030928] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 01/25/2022] [Accepted: 01/28/2022] [Indexed: 11/17/2022] Open
Abstract
Monoamine oxidases (MAOs) are attractive targets in drug design. The inhibition of one of the isoforms (A or B) is responsible for modulating the levels of different neurotransmitters in the central nervous system, as well as the production of reactive oxygen species. Molecules that act selectively on one of the MAO isoforms have been studied deeply, and coumarin has been described as a promising scaffold. In the current manuscript we describe a comparative study between 3-phenylcoumarin (endo coumarin-resveratrol-inspired hybrid) and trans-6-styrylcoumarin (exo coumarin-resveratrol-inspired hybrid). Crystallographic structures of both compounds were obtained and analyzed. 3D-QSAR models, in particular CoMFA and CoMSIA, docking simulations and molecular dynamics simulations have been performed to support and better understand the interaction of these molecules with both MAO isoforms. Both molecules proved to inhibit MAO-B, with trans-6-styrylcoumarin being 107 times more active than 3-phenylcoumarin, and 267 times more active than trans-resveratrol.
Collapse
|
7
|
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion? Future Med Chem 2021; 13:1301-1309. [PMID: 34137271 DOI: 10.4155/fmc-2021-0119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative diseases and the leading causes of dementia worldwide. The etiology of these multifactorial pathologies is not completely known. The available therapeutic approaches can cause temporary relief of symptoms but cannot slow down their progression or cure them. Life-changing therapeutic solutions are urgently needed, as the number of people suffering from these pathologies has been increasing quickly over the last few decades. Several targets are being studied, and innovative approaches are being pursued to find new therapeutic options. This overview is focused on the most recent information regarding the paradigm of using multitarget compounds to treat both Alzheimer's and Parkinson's disease.
Collapse
|
8
|
Pourshojaei Y, Eskandari K, Asadipour A. Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents. Mini Rev Med Chem 2019; 19:1577-1598. [DOI: 10.2174/1389557519666190719143112] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 06/02/2019] [Accepted: 06/25/2019] [Indexed: 12/19/2022]
Abstract
:
Alzheimer, a progressive disease, is a common term for memory loss which interferes with
daily life through severe influence on cognitive abilities. Based on the cholinergic hypothesis, and Xray
crystallographic determination of the structure of acetylcholinesterase (AChE) enzyme, the level of
acetylcholine (ACh, an important neurotransmitter associated with memory) in the hippocampus and
cortex area of the brain has a direct effect on Alzheimer. This fact encourages scientists to design and
synthesize a wide range of acetylcholinesterase inhibitors (AChEIs) to control the level of ACh in the
brain, keeping in view the crystallographic structure of AChE enzyme and drugs approved by the Food
and Drug Administration (FDA).
:
AChEIs have slightly diverse pharmacological properties, but all of them work by inhibiting the segregation
of ACh by blocking AChE. We reviewed significant scaffolds introduced as AChEIs. In some
studies, the activity against butyrylcholinesterase (BuChE) has been evaluated as well because BuChE
is a similar enzyme to neuronal acetylcholinesterase and is capable of hydrolyzing ACh. In order to
study AChEIs effectively, we divided them structurally into 12 classes and briefly explained effective
AChEIs and compared their activities against AChE enzyme.
Collapse
Affiliation(s)
- Yaghoub Pourshojaei
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Khalil Eskandari
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Ali Asadipour
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
9
|
Wang N, Qiu P, Cui W, Yan X, Zhang B, He S. Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present). Curr Med Chem 2019; 26:5684-5710. [DOI: 10.2174/0929867326666181203124102] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 08/03/2018] [Accepted: 11/03/2018] [Indexed: 12/21/2022]
Abstract
:
Since the last century, when scientists proposed the lock-and-key model, the discovery of
drugs has focused on the development of drugs acting on single target. However, single-target drug
therapies are not effective to complex diseases with multi-factorial pathogenesis. Moreover, the
combination of single-target drugs readily causes drug resistance and side effects. In recent years,
multi-target drugs have increasingly been represented among FDA-approved drugs. Alzheimer’s
Disease (AD) is a complex and multi-factorial disease for which the precise molecular mechanisms
are still not fully understood. In recent years, rational multi-target drug design methods, which combine
the pharmacophores of multiple drugs, have been increasingly applied in the development of
anti-AD drugs. In this review, we give a brief description of the pathogenesis of AD and provide
detailed discussions about the recent development of chemical structures of anti-AD agents (2013 up
to present) that have multiple targets, such as amyloid-β peptide, Tau protein, cholinesterases,
monoamine oxidase, β-site amyloid-precursor protein-cleaving enzyme 1, free radicals, metal ions
(Fe2+, Cu2+, Zn2+) and so on. In this paper, we also added some novel targets or possible pathogenesis
which have been reported in recent years for AD therapy. We hope that these findings may provide
new perspectives for the pharmacological treatment of AD.
Collapse
Affiliation(s)
- Ning Wang
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| | - Panpan Qiu
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| | - Wei Cui
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| | - Xiaojun Yan
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| | - Bin Zhang
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| | - Shan He
- Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Ningbo University, Ningbo 315211, China
| |
Collapse
|
10
|
Mathew B, Parambi DGT, Mathew GE, Uddin MS, Inasu ST, Kim H, Marathakam A, Unnikrishnan MK, Carradori S. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Arch Pharm (Weinheim) 2019; 352:e1900177. [PMID: 31478569 DOI: 10.1002/ardp.201900177] [Citation(s) in RCA: 86] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 07/26/2019] [Accepted: 08/01/2019] [Indexed: 01/07/2023]
Abstract
No drug has been approved to prevent neuronal cell loss in patients suffering from Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of the underlying molecular causes, therapies target cognitive functional improvement and motor fluctuation control. Drug design strategies that adopt the "one protein, one target" philosophy fail to address the multifactorial aetiologies of neurodegenerative disorders such as AD and PD optimally. On the contrary, restoring neurotransmitter levels by combined combinatorial inhibition of cholinesterases, monoamine oxidases, and adenosine A2A A receptors, in conjunction with strategies to counter oxidative stress and beta-amyloid plaque accumulation, would constitute a therapeutically robust, multitarget approach. This extensive review delineates the therapeutic advantages of combining dual-acting molecules that inhibit monoamine oxidases and cholinesterases and/or adenosine A2A A receptors, and describes the structure-activity relationships of compound classes that include, but are not limited to, alkaloids, coumarins, chalcones, donepezil-propargylamine conjugates, homoisoflavonoids, resveratrol analogs, hydrazones, and pyrazolines. In the wake of recent advances in network biology, in silico approaches, and omics, this review emphasizes the need to consider conceptually informed research strategies for drug discovery, in the context of the mounting burden posed by chronic neurodegenerative diseases with complex aetiologies and pathophysiologies involving multiple signalling pathways and numerous drug targets.
Collapse
Affiliation(s)
- Bijo Mathew
- Department of Pharmaceutical Chemistry Research Lab, Division of Drug Design and Medicinal Chemistry, Ahalia School of Pharmacy, Palakkad, India
| | - Della G T Parambi
- Department of Pharmaceutical Chemistry, Jouf University, Sakaka, Saudi Arabia
| | - Githa E Mathew
- Department of Pharmacology, Grace College of Pharmacy, Palakkad, India
| | - Md Sahab Uddin
- Department of Pharmacy, Southeast University, Dhaka, Bangladesh.,Pharmakon Neuroscience Research Network, Dhaka, Bangladesh
| | - Sini T Inasu
- Department of Pharmaceutical Chemistry Research Lab, Division of Drug Design and Medicinal Chemistry, Ahalia School of Pharmacy, Palakkad, India
| | - Hoon Kim
- Department of Pharmacy and Research, Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon, Republic of Korea
| | - Akash Marathakam
- Department of Pharmaceutical Chemistry, National College of Pharmacy, Calicut, India
| | | | - Simone Carradori
- Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy
| |
Collapse
|
11
|
Guglielmi P, Carradori S, Ammazzalorso A, Secci D. Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? Expert Opin Drug Discov 2019; 14:995-1035. [PMID: 31268358 DOI: 10.1080/17460441.2019.1637415] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson's disease. They can, based on their chemical structure and mechanism of inhibition, be categorized into reversible and irreversible agents. Areas covered: This review provides a comprehensive update on the development state of selective MAO-B inhibitors describing the results, structures, structure-activity relationships (SARs) and Medicinal chemistry strategies as well as the related shortcomings over the past five years. Expert opinion: Researchers have explored and implemented new and old chemical scaffolds achieving high inhibitory potencies and isoform selectivity. Most of them were characterized and proposed as multitarget agents able to act at different levels (including AChE inhibition, H3R or A2AR antagonism, antioxidant and chelating properties, Aβ1-42 aggregation reduction) in the network of aetiologies of neurodegenerative disorders. These results can also be used to avoid 'cheese-reaction' effects and the occurrence of serotonergic syndrome in patients.
Collapse
Affiliation(s)
- Paolo Guglielmi
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma , Rome , Italy
| | - Simone Carradori
- Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara , Chieti , Italy
| | | | - Daniela Secci
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma , Rome , Italy
| |
Collapse
|
12
|
Sivakumar M, Saravanan K, Saravanan V, Sugarthi S, kumar SM, Alhaji Isa M, Rajakumar P, Aravindhan S. Discovery of new potential triplet acting inhibitor for Alzheimer’s disease via X-ray crystallography, molecular docking and molecular dynamics. J Biomol Struct Dyn 2019; 38:1903-1917. [DOI: 10.1080/07391102.2019.1620128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
| | - Kandasamy Saravanan
- X-Ray Crystallography and Computational Molecular Biology Lab, Department of Physics, Periyar University, Salem, India
| | | | - Srinivasan Sugarthi
- Department of Physics and Nanotechnology, SRM Institute of Science and Technology, Kattankulathur, Kancheepuram, Tamil Nadu, India
| | | | - Mustafa Alhaji Isa
- Bioinformatics and Computational Biology Lab, Department of Microbiology, Faculty of Sciences, University of Maiduguri, Maiduguri, Nigeria
| | - Perumal Rajakumar
- Department of Organic Chemistry, University of Madras, Chennai, India
| | | |
Collapse
|
13
|
Yang J, Zhang P, Hu Y, Liu T, Sun J, Wang X. Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents. J Enzyme Inhib Med Chem 2019; 34:651-656. [PMID: 30746966 PMCID: PMC6374920 DOI: 10.1080/14756366.2019.1574297] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Alzheimer's disease, a neurodegenerative illness, has the extremely complex pathogenesis. Accumulating evidence indicates there is a close relationship between several enzymes and Alzheimer's disease. Various substituted 3-arylcoumarin derivatives were synthesised, and their in vitro activity, including cholinesterase inhibitory activity, monoamine oxidase inhibitory activity, and antioxidant activity were investigated. Most of the compounds exhibited high activity; therefore 3-arylcoumarin compounds have the potential as drug candidates for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Jie Yang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Pingping Zhang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Yuheng Hu
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Teng Liu
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Jie Sun
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Xiaojing Wang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of MateriaMedica , Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| |
Collapse
|
14
|
Gomes LR, Low JN, van Mourik T, da Silveira Pinto LS, de Souza MV, Wardell JL. Crystal structures, Hirsfeld surface analysis and a computational study of four ethyl 2-oxo-2 H-chromene-3-carboxylate derivatives: a survey of organyl 2-oxo-2 H-chromene-3-carboxylate structures. Z KRIST-CRYST MATER 2019. [DOI: 10.1515/zkri-2018-2117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Crystal structures, Hirshfeld surface analysis and a computational study have been carried out on 2-oxo-2H-chromene-3-carboxylates. Crystal structures are reported for ethyl R-2-oxo-2H-chromene-3-carboxylate derivatives, 2a: R=6-Me, 2b: 7-Me, 2c: 7-Me, 2d: R=7-MeO. In contrast to 2-oxo-2H-chromene-3-carboxamides, 1, in which classical intramolecular N–H···O hydrogen bonds stabilize planar structures and hinder rotation of the amido group out of the coumarin plane in 2, without an equivalent hydrogen bond, there is a greater rotational freedom of the carboxylate group. The interplanar angles between the coumarin core and its attached –C(O)–R substituent in crystalline 2a, 2b, 2c and 2d are 10.41(6), 36.65(6), 10.4(2) and 5.64(6)°, respectively, with distances between the carbonyl oxygen atoms of 2.8255(16), 2.9278(16), 4.226(2) and 2.8328(14) Å, respectively. A theoretical study of molecular conformations was carried out at the M06-2X density level with the 6-31+G(d) and aug-cc-pVTZ basis sets, in methanol solution modeled by PCM, indicated that the most stable conformations had the carbonyl group of the ester in the plane of the coumarin core: the s-cis arrangement of the ester carbonyl and the 2-oxo moieties being the slightly more stable than the s-trans form by less than 0.5 kcal/mol. The experimental conformations of 2a and 2d match well the low energy s-cis arrangement, and 2c matches the slightly lesser stable s-trans arrangement found in the theoretical study. A survey of the molecular conformations of more than 50 2H-chromene-3-carboxylates derivatives in the CCDC data base indicated two distinct groupings of conformations, s-cis and s-trans, each with interplanar angles <30°.
Collapse
Affiliation(s)
- Ligia R. Gomes
- FP-ENAS-Faculdade de Ciências de Saúde, Escola Superior de Saúde da UFP, Universidade Fernando Pessoa , Rua Carlos da Maia, 296 , P-4200-150 Porto , Portugal
- REQUIMTE, Departamento de Química e Bioquímica , Faculdade de Ciências da Universidade do Porto , Rua do Campo Alegre, 687 , P-4169-007, Porto , Portugal
| | - John N. Low
- Department of Chemistry , University of Aberdeen , Meston Walk, Old Aberdeen, AB24 3UE , Scotland , UK
| | - Tanja van Mourik
- School of Chemistry, University of St. Andrews , North Haugh, St. Andrews, Fife KY16 9ST , Scotland , UK
| | - Ligia S. da Silveira Pinto
- Universidade Federal do Rio de Janeiro, Instituto de Química , Departamento de Química Orgânica , CP 68563, 21945-970 , Rio de Janeiro , Brazil
- Instituto de Tecnologia em Fármacos e Farmanguinhos, Fundação Oswaldo Cruz , 21041-250 Rio de Janeiro, RJ , Brazil
| | - Marcus V.N. de Souza
- Instituto de Tecnologia em Fármacos e Farmanguinhos, Fundação Oswaldo Cruz , 21041-250 Rio de Janeiro, RJ , Brazil
| | - Jámes L. Wardell
- Department of Chemistry , University of Aberdeen , Meston Walk, Old Aberdeen, AB24 3UE , Scotland , UK
- Instituto de Tecnologia em Fármacos e Farmanguinhos, Fundação Oswaldo Cruz , 21041-250 Rio de Janeiro, RJ , Brazil
| |
Collapse
|
15
|
Delogu GL, Pintus F, Mayán L, Matos MJ, Vilar S, Munín J, Fontenla JA, Hripcsak G, Borges F, Viña D. MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations. MEDCHEMCOMM 2017; 8:1788-1796. [PMID: 30108888 PMCID: PMC6084085 DOI: 10.1039/c7md00311k] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Accepted: 07/05/2017] [Indexed: 11/21/2022]
Abstract
Monoamine oxidase (MAO) is an enzyme responsible for metabolism of monoamine neurotransmitters which play an important role in brain development and function. This enzyme exists in two isoforms, and it has been demonstrated that MAO-B activity, but not MAO-A activity, increases with aging. MAO inhibitors show clinical value because besides the monoamine level regulation they reduce the formation of by-products of the MAO catalytic cycle, which are toxic to the brain. A series of 2-phenylbenzofuran derivatives was designed, synthesized and evaluated against hMAO-A and hMAO-B enzymes. A bromine substituent was introduced in the 2-phenyl ring, whereas position 5 or 7 of the benzofuran moiety was substituted with a methyl group. Most of the tested compounds inhibited preferentially MAO-B in a reversible manner, with IC50 values in the low micro or nanomolar range. The 2-(2'-bromophenyl)-5-methylbenzofuran (5) was the most active compound identified (IC50 = 0.20 μM). In addition, none of the studied compounds showed cytotoxic activity against the human neuroblastoma cell line SH-SY5Y. Molecular docking simulations were used to explain the observed hMAO-B structure-activity relationship for this type of compounds.
Collapse
Affiliation(s)
- G L Delogu
- Department of Life Sciences and Environment - Section of Pharmaceutical Sciences - University of Cagliari, 09124 Cagliari, Italy.
| | - F Pintus
- Department of Life Sciences and Environment - Section of Pharmaceutical Sciences - University of Cagliari, 09124 Cagliari, Italy.
| | - L Mayán
- Department of Pharmacology - CIMUS University of Santiago de Compostela Avda Barcelona s/n, Campus Vida, 15782 Santiago de Compostela, Spain.
- Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - M J Matos
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - S Vilar
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
- Department of Biomedical Informatics, Columbia University, Medical Center of New York, 10032 New York, USA
| | - J Munín
- Department of Pharmacology - CIMUS University of Santiago de Compostela Avda Barcelona s/n, Campus Vida, 15782 Santiago de Compostela, Spain.
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - J A Fontenla
- Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - G Hripcsak
- Department of Biomedical Informatics, Columbia University, Medical Center of New York, 10032 New York, USA
| | - F Borges
- CIQUP/Department of Chemistry and Biochemistry, University of Porto, 4169-007, Portugal
| | - D Viña
- Department of Pharmacology - CIMUS University of Santiago de Compostela Avda Barcelona s/n, Campus Vida, 15782 Santiago de Compostela, Spain.
| |
Collapse
|
16
|
Costas-Lago MC, Besada P, Rodríguez-Enríquez F, Viña D, Vilar S, Uriarte E, Borges F, Terán C. Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors. Eur J Med Chem 2017; 139:1-11. [PMID: 28797881 DOI: 10.1016/j.ejmech.2017.07.045] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 07/19/2017] [Accepted: 07/21/2017] [Indexed: 10/19/2022]
Abstract
Compounds of hybrid structure pyridazine-coumarin were discovered as potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B). These compounds were synthesized in good yield following a multistep approach based on Knoevenagel reaction and using as key intermediate pyridazinone 16, which was obtained from maleic anhydride and furan. Compounds 9b and 9d are the most active compounds of these series, with IC50 values in the sub-micromolar range, and lack of cytotoxic effects. Theoretical calculation of ADME properties also suggested a good pharmacokinetic profile for both compounds. Docking simulations provided insights into enzyme inhibitor interactions and allowed us to rationalize the observed structure-activity relationships (SARs).
Collapse
Affiliation(s)
- María Carmen Costas-Lago
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310 Vigo, Spain
| | - Pedro Besada
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310 Vigo, Spain
| | - Fernanda Rodríguez-Enríquez
- Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS) Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Dolores Viña
- Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS) Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Santiago Vilar
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Eugenio Uriarte
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile, 7500912 Santiago, Chile
| | - Fernanda Borges
- CIQUP/Departamento de Química e Bioquímica, Faculdade de Ciencias, Universidade do Porto, 4169-007 Porto, Portugal
| | - Carmen Terán
- Departamento de Química Orgánica and Instituto de Investigación Sanitaria Galicia Sur (IISGS), Universidade de Vigo, 36310 Vigo, Spain.
| |
Collapse
|
17
|
Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer’s disease. Future Med Chem 2017; 9:811-832. [DOI: 10.4155/fmc-2017-0036] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Accumulating evidence indicates a solid relationship between several enzymes and Alzheimer’s disease. Cholinesterases and monoamine oxidases are closely associated with the disease symptomatology and progression and have been tackled simultaneously using several multifunctional ligands. This design strategy offers great chances to alter the course of Alzheimer’s disease, in addition to alleviation of the symptoms. More than 15 years of research has led to the identification of various dual cholinesterase/monoamine oxidase inhibitors, while some showing positive outcomes in clinical trials, thus giving rise to additional research efforts in the field. The aim of this review is to provide an update on the novel dual inhibitors identified recently and to shed light on their therapeutic potential.
Collapse
|
18
|
Vilar S, Quezada E, Uriarte E, Costanzi S, Borges F, Viña D, Hripcsak G. Computational Drug Target Screening through Protein Interaction Profiles. Sci Rep 2016; 6:36969. [PMID: 27845365 PMCID: PMC5109486 DOI: 10.1038/srep36969] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Accepted: 10/24/2016] [Indexed: 11/11/2022] Open
Abstract
The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC50 values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC50 in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin-3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety.
Collapse
Affiliation(s)
- Santiago Vilar
- Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032, USA.,Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Elías Quezada
- CIQUP, Department of Chemistry &Biochemistry, Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal
| | - Eugenio Uriarte
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Stefano Costanzi
- Department of Chemistry, American University, 20016 Washington, DC, USA
| | - Fernanda Borges
- CIQUP, Department of Chemistry &Biochemistry, Faculty of Sciences, University of Porto, 4169-007, Porto, Portugal
| | - Dolores Viña
- Department of Pharmacology, CIMUS, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - George Hripcsak
- Department of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032, USA
| |
Collapse
|
19
|
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease. Eur J Med Chem 2016; 128:332-345. [PMID: 27876467 DOI: 10.1016/j.ejmech.2016.10.060] [Citation(s) in RCA: 120] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 10/26/2016] [Accepted: 10/27/2016] [Indexed: 11/22/2022]
Abstract
Alzheimer's disease (AD) is a multifactorial neurological disorder among elderly people and combinatorial factors such as genetic, lifestyle, and environmental are involved in onset and disease progression. It has been demonstrated that loss of cholinergic transmission is one of the most significant causes of AD. One strategy currently being investigated for the development of new therapeutics relates to the enhancement of cholinergic system through several ways. At this juncture, anticholinesterase inhibitors have absorbed lots of attention and different marketed drugs such as donepezil, rivastigmine, tacrine, and galantamine have been developed. 9-Amino-1,2,3,4-tetrahydroacridine known as tacrine was introduced in 1945 as an efficient anticholinesterase agent. The mechanism of action of tacrine was proved to inhibit the metabolism of acetylcholine and therefore extending its activity and raising levels in the cerebral cortex. However, extensive use of tacrine was limited since it showed various side effects and toxicity. Thus, lots of efforts were carried out to prepare tacrine analogues to overcome the related adverse effects. This review describes differently synthesized tacrine-based scaffolds as cholinesterase inhibitors to manage Alzheimer's disease (AD).
Collapse
|
20
|
Gomes LR, Low JN, Fonseca A, Matos MJ, Borges F. Crystal structures of three 6-substituted coumarin-3-carboxamide derivatives. Acta Crystallogr E Crystallogr Commun 2016; 72:926-32. [PMID: 27555933 PMCID: PMC4992908 DOI: 10.1107/s2056989016008665] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 05/29/2016] [Indexed: 11/21/2022]
Abstract
Three coumarin derivatives, viz. 6-methyl-N-(3-methyl-phen-yl)-2-oxo-2H-chromene-3-carboxamide, C18H15NO3 (1), N-(3-meth-oxy-phen-yl)-6-methyl-2-oxo-2H-chromene-3-carboxamide, C18H15NO4 (2), and 6-meth-oxy-N-(3-meth-oxy-phen-yl)-2-oxo-2H-chromene-3-carboxamide, C18H15NO5 (3), were synthesized and structurally characterized. The mol-ecules display intra-molecular N-H⋯O and weak C-H⋯O hydrogen bonds, which probably contribute to the approximate planarity of the mol-ecules. The supra-molecular structures feature C-H⋯O hydrogen bonds and π-π inter-actions, as confirmed by Hirshfeld surface analyses.
Collapse
Affiliation(s)
- Lígia R. Gomes
- REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Rua do Campo Alegre, 687, P-4169-007, Porto, Portugal
- FP-ENAS-Faculdade de Ciências de Saúde, Escola Superior de Saúde da UFP, Universidade Fernando Pessoa, Rua Carlos da Maia, 296, P-4200-150 Porto, Portugal
| | - John Nicolson Low
- Department of Chemistry, University of Aberdeen, Meston Walk, Old Aberdeen AB24 3UE, Scotland
| | - André Fonseca
- CIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal
| | - Maria João Matos
- CIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal
| | - Fernanda Borges
- CIQUP/Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal
| |
Collapse
|
21
|
Vila N, Besada P, Viña D, Sturlese M, Moro S, Terán C. Synthesis, biological evaluation and molecular modeling studies of phthalazin-1(2H)-one derivatives as novel cholinesterase inhibitors. RSC Adv 2016. [DOI: 10.1039/c6ra03841g] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of donepezil analogues based on phthalazin-1(2H)-one scaffold was studied as hChEIs. The biological results revealed that the structural modifications proposed significantly affected ChE inhibitory potency as well as selectivity AChE/BuChE.
Collapse
Affiliation(s)
- Noemí Vila
- Departamento de Química Orgánica
- Universidade de Vigo
- Vigo
- Spain
- Instituto de Investigación biomédica (IBI)
| | - Pedro Besada
- Departamento de Química Orgánica
- Universidade de Vigo
- Vigo
- Spain
- Instituto de Investigación biomédica (IBI)
| | - Dolores Viña
- Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS)
- Universidade de Santiago de Compostela
- Santiago de Compostela
- Spain
| | - Mattia Sturlese
- Molecular Modeling Section (MMS)
- Dipartimento di Scienze del Farmaco
- Università degli Studi di Padova
- Padova
- Italy
| | - Stefano Moro
- Molecular Modeling Section (MMS)
- Dipartimento di Scienze del Farmaco
- Università degli Studi di Padova
- Padova
- Italy
| | - Carmen Terán
- Departamento de Química Orgánica
- Universidade de Vigo
- Vigo
- Spain
- Instituto de Investigación biomédica (IBI)
| |
Collapse
|
22
|
Fonseca A, Matos MJ, Reis J, Duarte Y, Gutiérrez M, Santana L, Uriarte E, Borges F. Exploring coumarin potentialities: development of new enzymatic inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold. RSC Adv 2016. [DOI: 10.1039/c6ra05262b] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Novel 6-methyl-3-carboxamidocoumarins were synthesized by an effective three step synthetic strategy and screened towards MAO, AChE and BuChE enzymes.
Collapse
Affiliation(s)
- A. Fonseca
- CIQUP/Departamento de Química e Bioquímica
- Faculdade de Ciências
- Universidade do Porto
- Porto
- Portugal
| | - M. J. Matos
- CIQUP/Departamento de Química e Bioquímica
- Faculdade de Ciências
- Universidade do Porto
- Porto
- Portugal
| | - J. Reis
- CIQUP/Departamento de Química e Bioquímica
- Faculdade de Ciências
- Universidade do Porto
- Porto
- Portugal
| | - Y. Duarte
- Laboratorio de Síntesis Orgánica
- Instituto de Química de Recursos Naturales Universidad de Talca
- Talca
- Chile
| | - M. Gutiérrez
- Laboratorio de Síntesis Orgánica
- Instituto de Química de Recursos Naturales Universidad de Talca
- Talca
- Chile
| | - L. Santana
- Departamento de Química Orgánica
- Faculdade de Farmacia
- Universidade de Santiago de Compostela
- Santiago de Compostela
- Spain
| | - E. Uriarte
- Departamento de Química Orgánica
- Faculdade de Farmacia
- Universidade de Santiago de Compostela
- Santiago de Compostela
- Spain
| | - F. Borges
- CIQUP/Departamento de Química e Bioquímica
- Faculdade de Ciências
- Universidade do Porto
- Porto
- Portugal
| |
Collapse
|
23
|
Skalicka-Woźniak K, Orhan IE, Cordell GA, Nabavi SM, Budzyńska B. Implication of coumarins towards central nervous system disorders. Pharmacol Res 2015; 103:188-203. [PMID: 26657416 DOI: 10.1016/j.phrs.2015.11.023] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 11/28/2015] [Accepted: 11/29/2015] [Indexed: 01/11/2023]
Abstract
Coumarins are widely distributed, plant-derived, 2H-1-benzopyran-2-one derivatives which have attracted intense interest in recent years as a result of their diverse and potent pharmacological properties. Particularly, their effects on the central nervous system (CNS) have been established. The present review discusses the most important pharmacological effects of natural and synthetic coumarins on the CNS, including their interactions with benzodiazepine receptors, their dopaminergic and serotonergic affinity, and their ability to inhibit cholinesterases and monoamine oxidases. The structure-activity relationships pertaining to these effects are also discussed. This review posits that natural or synthetic coumarins have the potential for development in the therapy of psychiatric and neurodegenerative disorders, including Alzheimer's and Parkinson's diseases, schizophrenia, anxiety, epilepsy, and depression.
Collapse
Affiliation(s)
- Krystyna Skalicka-Woźniak
- Department of Pharmacognosy with Medicinal Plant Unit, Medical University of Lublin, 1 Chodzki Str., 20-093 Lublin, Poland.
| | - Ilkay Erdogan Orhan
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey
| | - Geoffrey A Cordell
- Natural Products Inc., Evanston, IL 60203, USA; Department of Pharmaceutics, College of Pharmacy, University of FL, Gainesville, FL 32610, USA
| | - Seyed Mohammad Nabavi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Barbara Budzyńska
- Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland
| |
Collapse
|
24
|
Pau A, Catto M, Pinna G, Frau S, Murineddu G, Asproni B, Curzu MM, Pisani L, Leonetti F, Loza MI, Brea J, Pinna GA, Carotti A. Multitarget-Directed Tricyclic Pyridazinones as G Protein-Coupled Receptor Ligands and Cholinesterase Inhibitors. ChemMedChem 2015; 10:1054-70. [DOI: 10.1002/cmdc.201500124] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Indexed: 11/11/2022]
|
25
|
Potent and selective MAO-B inhibitory activity: Amino- versus nitro-3-arylcoumarin derivatives. Bioorg Med Chem Lett 2015; 25:642-8. [DOI: 10.1016/j.bmcl.2014.12.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 12/01/2014] [Accepted: 12/01/2014] [Indexed: 12/26/2022]
|